CFDE Data Portal | Search LINC01892

	Label	Description
	LINC01892 Gene (Entity type)	ENSG00000265514 - long intergenic non-protein coding RNA 1892
	GSE202434 GSE202438 talazoparib 3 v 11 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE224105 GSE224108 zearalenone 3 v 2 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE182680 GSE182683 dexamethasone 0 v 11 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE192750 adipose overexpression Grunt Fin PNMR OE 6 v 9 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE209533 disulfiram 0 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE236896 GSE237665 DNMT EZH2 inhibition 1 v 7 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE171826 rosiglitazone adipocyte 1 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE233679 nicotinamide 14 v 10 human dn Gene Set (Entity type)	A Gene Set from LINCS

LINC01892

ENSG00000265514 - long intergenic non-protein coding RNA 1892

GSE202434 GSE202438 talazoparib 3 v 11 human dn

A Gene Set from LINCS

GSE224105 GSE224108 zearalenone 3 v 2 human up

A Gene Set from LINCS

GSE182680 GSE182683 dexamethasone 0 v 11 human dn

A Gene Set from LINCS

GSE192750 adipose overexpression Grunt Fin PNMR OE 6 v 9 human dn

A Gene Set from LINCS

GSE209533 disulfiram 0 v 1 human up

A Gene Set from LINCS

GSE236896 GSE237665 DNMT EZH2 inhibition 1 v 7 human dn

A Gene Set from LINCS

GSE171826 rosiglitazone adipocyte 1 v 0 human up

A Gene Set from LINCS

GSE233679 nicotinamide 14 v 10 human dn

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.